

Joint Working Executive Summary

Published on <u>www.bayer.co.uk</u>

| Project | Redesign of Macular Service at Taunton & Somerset NHS Foundation Trust |
|----------------------|---|
| title | Redesign of Macular Service at radition & Somerset Wils Foundation Hust |
| Project | Taunton & Somerset Hospital NHS Foundation Trust |
| partners | |
| | Bayer plc |
| Project | The ophthalmology department at Taunton Hospital, part of Taunton & Somerset |
| summary | Hospital NHS Foundation Trust, is facing a number of issues with capacity to deliver its |
| | services, therefore a service redesign is being proposed to address these capacity issues. |
| | The project will involve: |
| | • Training for appropriate HCPs in the use of new imaging technology, and around giving treatment to patients according to agreed pathways |
| | Implementation of new technology which aims to allow improvements in the management of medical retina patients |
| | Implementation of recognised quality improvement methodologies to continuously develop and improve services, aiming to optimise outcomes for |
| | patients Initiation of virtual clinics for medical retina patients as well as for patients |
| | referred from the diabetic screening service, and additional macular treatment clinics to be initiated at Musgrove Park Hospital |
| | These changes will be implemented by the redesign of patient pathways and embedded via the use of improvement methodologies. |
| Expected | Benefits for Patients: |
| benefits to | Aim to improve patient waiting times and access to treatment following |
| patients, the NHS | diagnosis |
| and Bayer | Aim to improve patient experience in streamlined virtual clinics The potential to improve outcomes by being treated according to national |
| | guidelines |
| | Access to additional diagnostic equipment and improved clinical pathways at the local hospital should mean fewer out of area referrals and therefore facilitate more care closer to home for patients |
| | |

Page 1 of 2

| | Benefits for the NHS: |
|------------|--|
| | Virtual review of patient referrals from Regional and National Screening Programmes aims to reduce waiting times for these patients and speed up time to diagnosis and treatment according to national guidelines Workforce redesign in conjunction with pathway redesign aims to allow the Trust to manage resources more effectively to optimise patient outcomes The addition of new technology aims to reduce the number of out of area referrals |
| | Benefits for Bayer: Aim to improve reputation by demonstrating commitment and willingness to invest in improving patient care through a fully transparent joint working agreement with Taunton & Somerset Aim to improve NICE-approved medicines optimisation of injectable therapies, of which Bayer has one, in line with national guidelines due to improving capacity for provision Aim to build a better understanding of Taunton & Somerset and patients' needs |
| Start date | October 2017 |

Date of Preparation: September 2024 Job bag number: PP-PF-OPHT-GB-1183

Page 2 of 2